Understand the source comparison
Do Peptides Help with Inflammation — Comparison Across Mechanisms
Thymosin Alpha-1 NF- B inhibition, Treg upregulation Systemic immune modulation Phase 3 RCTs in sepsis 47% reduction in IL-6, 18% mortality reduction Gold-standard immunomodulator for systemic inflammation KPV NF- B translocation block Gastrointestinal tract
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymosin Alpha-1
- NF-κB inhibition, Treg upregulation
- Systemic immune modulation
- Phase 3 RCTs in sepsis
- 47% reduction in IL-6, 18% mortality reduction
- Gold-standard immunomodulator for systemic inflammation
- KPV
- NF-κB translocation block
- Gastrointestinal tract, skin
- Preclinical + limited human case series
- 52% reduction in colonic inflammation scores (murine)
- Promising for IBD, lacks large-scale human trials
- BPC-157
- FAK-paxillin pathway activation
- Tendons, ligaments, GI mucosa
- Extensive animal studies, anecdotal human use
- Accelerated healing timelines, reduced local cytokines
- High anecdotal efficacy, formal human trials needed
- Dihexa
- HGF receptor agonism, microglial suppression
- Central nervous system
- Preclinical cognitive models
- 41% reduction in hippocampal IL-1β
- Unique CNS anti-inflammatory with neurogenesis overlap
- Cartalax
- MMP inhibition, chondrocyte gene modulation
- Cartilage and connective tissue
- Russian clinical registry data
- 34% mobility improvement, 29% synovial marker reduction
- Bioregulator class. Regulatory acceptance varies by region